Evogene Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: As of June 30, 2026, Evogene held approximately $9.3 million in cash and cash equivalents.

Cash Usage: Consolidated cash usage for Q2 2026 was around $2.1 million, with an expected full-year cash burn of $8.5 million to $9.5 million.

Net Loss: The net loss for Q2 2026 was approximately $1.8 million, a significant improvement from $4.7 million in Q2 2025. The loss for the first half of 2026 remained stable at about $7.7 million.

Revenue: Total revenues for the first half of 2026 were approximately $0.7 million, down from $2.9 million in the same period in 2025, primarily due to lower revenue from Casterra and the conclusion of the AgPlenus agreement with Bayer.

2Strategic Updates and Business Highlights

Transformation Initiatives: Evogene has streamlined operations, reducing headcount from 117 to 38, and shifted focus to its AI-driven platform, ChemPass, for drug and crop protection development.

Partnerships: Secured six key drug development agreements with biotechnology firms and academic institutions, validating the ChemPass AI platform.

Product Development: Advanced internal drug discovery programs and crop protection initiatives, including the development of a novel fungicide targeting Septoria.

Financial Maneuvering: Raised approximately $11.1 million in new capital and monetized Lavie Bio for $15.25 million, which supports ongoing strategic initiatives.

3Forward Guidance and Outlook

Growth Expectations: The company anticipates further reductions in cash burn and aims to generate revenue from ongoing drug development collaborations as molecules progress through the pipeline.

Upcoming Milestones: Plans to initiate preclinical trials for internal drug candidates in the second half of 2027, with expectations for continued advancements in both pharma and agriculture sectors.

4Bad News, Challenges, or Points of Concern

Shareholder Dissatisfaction: A group of dissident shareholders is seeking to replace the Board, indicating potential instability and dissatisfaction with the current leadership.

Revenue Decline: Significant drop in revenues compared to previous years, attributed to the winding down of noncore subsidiaries and reduced sales from Casterra.

Market Competition: The competitive landscape in small molecule discovery remains challenging, with Evogene needing to demonstrate the unique value of its technology to secure further partnerships and collaborations.

5Notable Q&A Insights

Investor Relations: Management acknowledged the need for enhanced investor outreach and plans to engage more actively with potential investors to communicate the company’s progress and value.

Field Trials and Development Timelines: Management indicated that field trials for the Septoria program are in the validation stage, with greenhouse testing expected soon, and preclinical trials for drug candidates are anticipated to start in the second half of 2027.

Future Collaborations: Ofer Haviv expressed optimism about ongoing discussions with pharmaceutical companies and the potential for new collaborations, emphasizing the unique positioning of Evogene's technology in the market. Overall, Evogene is undergoing a significant transformation aimed at enhancing operational efficiency and focusing on high-potential areas in pharmaceuticals and agriculture, despite facing challenges related to shareholder sentiment and declining revenue.